Abstract 2109P
Background
Vitamin deficiencies and supplement intake is discussed controversially in oncology. Therefore, we aimed to investigate vitamin D, A and E levels and their correlation with clinical characteristics and symptomatic burden in a large pan-cancer cohort.
Methods
25-hydroxy-vitamin D, vitamin A, and vitamin E levels were measured at treatment start in patients receiving palliative cancer treatment at the Medical University of Vienna (MUV) included in the “Biobanking Program for Personalized Immunotherapy” between May 2019 and March 2022. Measurements were performed using a chemiluminescence immunoassay (vitamin D) and high performance liquid chromatography (vitamin A, vitamin E) established at the Department of Laboratory Medicine (MUV). Cut off values defining the normal range were predefined as follows: vitamin D (75-250nmol/L), vitamin A (1.05-2.45μmol/L), vitamin E (12.0-42.0μmol/L). Symptom burden was assessed using the EORTC quality of life questionnaire QLQC-30 and its subscore assessing fatigue.
Results
Vitamin D, A, and E levels were measured in a total of 231 patients (92 females, 139 males, median age: 64 years [range: 23-89]). Median vitamin levels were as follows: vitamin D 66.9nmol/l (range: 10.4-186.0nmol/l), vitamin A 1.64μmol/l (range: 0.29-4.22μmol/l), and vitamin E 35.8μmol/l (range: 20.2-76.8μmol/l). Patients presented with vitamin D deficiencies in 138/231 (59.7%) and vitamin A deficiencies in 34/231 cases (14.7%). No vitamin E deficiencies were detected, however, 25/231 patients (24.2%) presented with vitamin E levels above normal. Vitamin A levels were increased in 26/231 patients (11.3%), while vitamin D levels above the upper limit of normal in 1/231 patient (0.4%). No correlations between vitamin levels and clinical characteristics at sample collection such as sex, age, tumor origin, symptom burden or fatigue were observed (p>0.05). Additionally, no correlation between vitamin levels and overall survival could be detected (p>0.05).
Conclusions
Even though vitamin deficiencies are common in patients with cancer, no influences of vitamin levels on symptom burden, fatigue or survival could be detected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association.
Disclosure
A.M. Starzer: Financial Interests, Personal, Invited Speaker, Lecture honoraria: AstraZeneca; Financial Interests, Institutional, Research Grant, Industry partner of institutional Christian Doppler Laboratory: Roche; Non-Financial Interests, Member, National Oncology Society: OeGHO; Non-Financial Interests, Member, Oncology society of USA: ASCO; Other, Travel support for conference participation: MSD, Lilly. M. Preusser: Financial Interests, Personal, Advisory Board: Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman, CMC Contrast, GSK, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, Gan & Lee Pharmaceuticals; Financial Interests, Institutional, Research Grant, Clinical Trials and research: Boehringer-Ingelheim, Bristol Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dohme, Novocure, GSK, AbbVie; Financial Interests, Institutional, Coordinating PI: PharmaMar; Non-Financial Interests, Leadership Role, Brain Tumor Group Chair (current): EORTC; Non-Financial Interests, Leadership Role, EANO Past-President (current): EANO; Non-Financial Interests, Other, Member Multi-Site Guideline Advisory Group: ASCO. A.S. Berghoff: Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck, AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06